Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;26(8):1804-1813.
doi: 10.1002/ejhf.3368. Epub 2024 Jul 9.

Plasma soluble fms-like tyrosine kinase-1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure

Melinda A Paterson  1 , Anna P Pilbrow  1 , Chris M Frampton  1 , Vicky A Cameron  1 , Richard W Troughton  1 , Chris J Pemberton  1 , Mayanna Lund  2 , Gerard P Devlin  3 , A Mark Richards  1   4 , Robert N Doughty  5 , Barry R Palmer  1   6
Affiliations
Free article

Plasma soluble fms-like tyrosine kinase-1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure

Melinda A Paterson et al. Eur J Heart Fail. 2024 Aug.
Free article

Abstract

Aims: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), components of the vascular endothelial growth factor (VEGF) system, play key roles in angiogenesis. Reports of elevated plasma levels of sFlt-1 and PlGF in coronary heart disease and heart failure (HF) led us to investigate their utility, and VEGF system gene single nucleotide polymorphisms (SNPs), as prognostic biomarkers in HF.

Methods and results: ELISA assays for sFlt-1, PlGF and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed on baseline plasma samples from the PEOPLE cohort (n = 890), a study of outcomes among patients after an episode of acute decompensated HF. Eight SNPs potentially associated with sFlt-1 or PlGF levels were genotyped. sFlt-1 and PlGF were assayed in 201 subjects from the Canterbury Healthy Volunteers Study (CHVS) matched to PEOPLE participants. All-cause death was the major endpoint for clinical outcome considered. In PEOPLE participants, mean plasma levels for both sFlt-1 (125 ± 2.01 pg/ml) and PlGF (17.5 ± 0.21 pg/ml) were higher (both p < 0.044) than in the CHVS cohort (81.2 ± 1.31 pg/ml and 15.5 ± 0.32 pg/ml, respectively). sFlt-1 was higher in HF with reduced ejection fraction compared to HF with preserved ejection fraction (p = 0.005). The PGF gene SNP rs2268616 was univariately associated with death (p = 0.016), and was also associated with PlGF levels, as was rs2268614 genotype. Cox proportional hazards modelling (n = 695, 246 deaths) showed plasma sFlt-1, but not PlGF, predicted survival (hazard ratio 6.44, 95% confidence interval 2.57-16.1; p < 0.001) in PEOPLE, independent of age, NT-proBNP, ischaemic aetiology, diabetic status and beta-blocker therapy.

Conclusions: Plasma sFlt-1 concentrations have potential as an independent predictor of survival and may be complementary to established prognostic biomarkers in HF.

Keywords: Heart failure; Mortality; Placental growth factor; Prognostic biomarkers; Single nucleotide polymorphism; sFlt‐1.

PubMed Disclaimer

References

    1. Zhou Y, Zhu X, Cui H, Shi J, Yuan G, Shi S, et al. The role of the VEGF family in coronary heart disease. Front Cardiovasc Med 2021;8:738325. https://doi.org/10.3389/fcvm.2021.738325
    1. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90:10705–10709. https://doi.org/10.1073/pnas.90.22.10705
    1. Matsumoto T, Uemura S, Takeda Y, Matsui M, Okada S, Nishida T, et al. An elevated ratio of placental growth factor to soluble fms‐like tyrosine kinase‐1 predicts adverse outcomes in patients with stable coronary artery disease. Intern Med 2013;52:1019–1027. https://doi.org/10.2169/internalmedicine.52.9073
    1. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;97:99–107. https://doi.org/10.1161/01.cir.97.1.99
    1. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Momomura SI, et al. Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 2009;131:186–191. https://doi.org/10.1016/j.ijcard.2007.10.050

MeSH terms